Radiation and study drug for hard-to-treat pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new medicine (TTI-101) combined with targeted radiation for people with pancreatic cancer that is either borderline or locally advanced. The goal is to see if this combination can shrink or control the cancer better than usual treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has not spread and is considered borderline or locally advanced by your doctor.
- You have finished at least one round of standard chemotherapy before starting this study (timing can be flexible with your doctor's okay).
- You are 18 or older and able to take care of yourself (ECOG score 2 or less).
- Your blood counts and organ function are within acceptable ranges, such as adequate white blood cells, platelets, and kidney/liver function.
- You can swallow pills and are willing to use effective birth control during and after the study.
- You have not had treatment for pancreatic cancer in the past 2 years (except the chemo for your current diagnosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a precise type of radiation therapy guided by MRI for people with locally advanced pancreatic cancer. It aims to treat the tumor while protecting nearby healthy tissue, potentially improving outcomes after chemotherapy.
This trial tests a special type of radiation that delivers a higher dose to the center of the tumor while limiting radiation to nearby healthy organs. It's for people with certain solid tumors that haven't spread widely or have only a few metastases.
This trial tests a new treatment that uses tiny alpha radiation sources placed directly into the tumor to destroy cancer cells. It is for people with pancreatic cancer that has not spread but cannot be removed surgically, and who have already tried at least one type of chemotherapy or cannot take more chemo.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.